A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection

Anna C. Nilsson, John Pullman, Piotr Napora, Kleber Luz, Anil Gupta, Jorge Draghi, Ana Karla Guzman Romero, Naresh Aggarwal, Galina Petrova, Juliana Ianus, Leen Vijgen, Jane Scott, Rekha Sinha, Sarah Rusch, Dymphy Huntjens, Kristi Bertzos, Marita Stevens, ROSE Study Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology